Pharmaceutical Products and Their Value in 2020 and Ahead
As drug prices and pharmaceutical spending in the U.S. continue to rise, public outcry demands improved strategies for making drug affordable. Value-based pricing emerges as a preferred alternative to prices determined by what the market will bear. In Value in Health, Ms. Kaltenboeck assesses the challenges of value-based pricing strategies, and describes alternatives with greater potential for impact than contracting strategies.
Access full article here.